Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast

This study has been terminated.
(Lack of Funding)
Sponsor:
Information provided by (Responsible Party):
University of Southern California
ClinicalTrials.gov Identifier:
NCT00556907
First received: November 8, 2007
Last updated: March 17, 2014
Last verified: March 2014

November 8, 2007
March 17, 2014
October 2007
December 2014   (final data collection date for primary outcome measure)
Feasibility. The primary efficacy endpoint will be reoperation (re-excision or mastectomy) rates following WLE or IORT [ Time Frame: 30 days ] [ Designated as safety issue: No ]
Feasibility. The primary efficacy endpoint will be reoperation (re-excision or mastectomy) rates following WLE or IORT [ Time Frame: 30 days ]
Complete list of historical versions of study NCT00556907 on ClinicalTrials.gov Archive Site
Safety endpoints: The overall serious adverse event rate will be assessed for all patients at stated follow-up periods. Complications associated with each of the following setting will be documented and reported separately [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Safety endpoints: The overall serious adverse event rate will be assessed for all patients at stated follow-up periods. Complications associated with each of the following setting will be documented and reported separately [ Time Frame: 2 years ]
Not Provided
Not Provided
 
Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast
Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast (TARGIT-DCIS Trial): Use of Mammography and Breast MRI to Identify Candidates for IORT.

We hypothesize that the combination of mammography and CE-MRI will improve the surgeon and radiologist's ability to define extent of disease prior to surgical resection, improve the odds of obtaining clear surgical margins, and increase the efficacy of IORT delivered immediately after initial surgical resection. In this investigation, we will determine whether or not patients deemed eligible for 'immediate" IORT based on mammography and CE-MRI can be successfully treated without the need for re-excision or additional radiotherapy due to inadequate surgical margins.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Breast Cancer
  • Radiation: Intraoperative radiotherapy
    20Gy to surface of tumor bed and 5Gy at depth of 1cm from surface of tumor bed
    Other Name: Intrabeam Photon Radiosurgery System and Applicators
  • Device: Intraoperative radiotherapy
    20gy to tumor bed, 5gy at depth of 1cm from surface of tumor bed
    Other Name: Intrabeam Photon Radiosurgery
1
Patients will receive IORT
Interventions:
  • Radiation: Intraoperative radiotherapy
  • Device: Intraoperative radiotherapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
22
November 2015
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with biopsy-proven DCIS, mammographic and CE-MRI evidence of DCIS measuring great then equal to 4cm, and a desire to receive breast conserving therapy, will be considered for participation in this study.
  • Patient history, physical examination findings, and demographics (sex, age, height, weight, bra size, etc.) will be performed and documented.

Inclusion Criteria for Initial Registration (all patients cohorts):

All cohorts

  • Signed informed consent and HIPAA documents
  • Female sex
  • Age great then equal to 40 years
  • Localized ductal carcinoma in situ
  • Clinically and/or histologically negative axillary lymph nodes
  • No imaging or clinical findings suggestive of invasive carcinoma.

Cohort 1 (Immediate IORT group)

  • Localized DCIS measuring less then equal to 4 cm on preoperative imaging.
  • Cohort 2 (Delayed IORT group)
  • Localized DCIS measuring less then equal to4 cm or less on surgical pathology
  • Delayed IORT could be performed for the explicit purpose of administering IORT or performed following re-excision of a previously operated breast to achieve clear surgical margins.
  • This cohort includes patients who were excluded from immediate IORT based on pre-operative imaging suggesting ineligibility for immediate IORT, but who are subsequently found to meet histological criteria (localized DCIS less then equal to 4 cm and no invasive cancer) for IORT based on surgical pathology.
  • Unifocal microinvasive (T1mic or invasive focus less then equal to 1mm in maximal diameter) is allowed following initial WLE if surgical pathology margins were less then equal to2 mm for both the invasive and non-invasive components.
  • Delayed IORT must be performed within 3 months of initial WLE.
  • Cohort 3 Subjects who received IORT at the time of initial WLE but whose surgical pathology showed them to be unsuitable candidates for IORT alone on the basis of:
  • DCIS measuring greater than 5 cm on surgical pathology.
  • T1a (less than 1 mm) or larger invasive carcinoma associated with extensive DCIS.
  • Surgical margins width less than1 mm.

Exclusion Criteria:

  • Male sex
  • Age less than 40
  • DCIS associated with any evidence of microinvasion or invasive carcinoma on pre-operative imaging or core biopsy of the breast or axillary nodes.
  • DCIS that is multicentric in the ipsilateral breast. Multicentricity will be defined at 2 or more lesions separated by more than 3 cm in the same breast.
  • Non-epithelial breast malignancies such as sarcoma or lymphoma
  • DCIS associated with diffuse suspicious or indeterminate microcalcifications
  • Pregnancy or lactation
  • Collagen vascular diseases, including Systemic lupus erythematosus, Systemic sclerosis (scleroderma), CREST Syndrome (calcinosis, Raynaud phenomenon, esophageal dysfunction, sclerodactyly, telangiectasia, and the presence of anticentromere antibodies), polymyositis, dermatomyositis with a CPK level above normal or with an active skin rash, inclusion-body myositis, or amyloidosis
  • Serious psychiatric or addictive disorders
Female
40 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00556907
1B-06-9
No
University of Southern California
University of Southern California
Not Provided
Principal Investigator: Heather Macdonald, MD University of Southern California
University of Southern California
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP